e16073 Background: Men who experience biochemical recurrence after curative therapy for prostate cancer are often treated with androgen deprivation therapy (ADT), though there is no proven survival benefit in this setting. Side effects of ADT negatively impact quality of life (QOL). There is interest in alternative therapies to control PSA without ADT side effects. In conjunction with clinical testing of prostate health cocktail (PHC), a combination herbal therapy for men with biochemically recurrent prostate cancer, we surveyed QOL in trial subjects who were still receiving PHC (n=11), or had moved on to ADT (n=12) or observation (n=16). Methods: Subjects were surveyed using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) instrument, in which respondents report their level of physical and psychological functioning during the past 7 days. The survey was completed in person, by phone, by mail or via online submission. Results: Of the 40 men (93% of total trial subjects) who responded to the survey, the median age was 66 (range 54-84) and PSA was 2.8 (range 1.1-84). 23% had received radiation as primary treatment, 25% radical prostatectomy, and 52% had received both. One patient was receiving radiation at the time of survey and was excluded. In the Physical Well-Being domain, which assesses energy, feeling ill, nausea, pain and trouble meeting needs, there was a significantly lower score among men receiving ADT (median 25; 95% CI 23.5-26.2) compared to those taking PHC (26.5; CI 24.2-27.8) or being observed (28; 26.4-28) (p =0.006). There was no significant difference among the groups in the other domains, though within the Prostate Cancer-Specific Concerns domain significantly more men indicated they were "not at all" able to have/maintain erections in the ADT group (11/12) compared to PHC (6/11) and observation (5/15) (p=0.009). Conclusions: Decisions about treatment for rising PSA levels after curative-intent therapy must be informed by therapeutic value as well as consideration for QOL. We found that men being treated with ADT have a significantly lower physical function score, and the relatively high QOL for patients on a clinical trial of an herbal supplement was similar to that of patients being observed. Clinical trial information: NCT00669656.
Toxicities, Quality of Life and MRI Response to Focal Salvage HDR Prostate Brachytherapy for Locally Recurrent Prostate Cancer after External-Beam Radiotherapy